From Wikipedia, the free encyclopedia
Jump to navigation Jump to search
WikiProject Pharmacology (Rated Start-class, Mid-importance)
WikiProject iconThis article is within the scope of WikiProject Pharmacology, a collaborative effort to improve the coverage of Pharmacology on Wikipedia. If you would like to participate, please visit the project page, where you can join the discussion and see a list of open tasks.
Start-Class article Start  This article has been rated as Start-Class on the project's quality scale.
 Mid  This article has been rated as Mid-importance on the project's importance scale.

approved for use in Type II diabetes

is use for PCOS approved? JWSchmidt 19:26, 21 Apr 2004 (UTC)

Not to my knowledge, but in several studies it proved very beneficial (like metformin, confirming again that insulin resistance is very central in PCOS; e.g. MedScape. JFW | T@lk 19:29, 21 Apr 2004 (UTC)

Does Wikipedia have any kind of policy about trying to indicate which uses for drugs are approved uses? JWSchmidt 17:27, 22 Apr 2004 (UTC)

Uhh—I'm reluctant to admit that I don't know what the main source for "Wikipedia policy" is. IMHO, this shouldn't be an issue, as "approval" differs between one country and the next. In the UK, it is at the discretion of the prescribing doctor to prescibe off-licence drugs (many do it, few admit it). As stated, I have not seriously looked into registration of thiazolidinediones for NASH and PCOS. If you feel this is important, please let me know. JFW | T@lk 19:23, 22 Apr 2004 (UTC)

Rosiglitazone for Alzheimer's[edit]

NIH funded a drug trial to test rosiglitazone in a controlled study with sugar pill one group and drug in another, etc. 18-month. MRI will be done to start off and at end of study.

Point is insulin may affect protein levels that make up the sticky plaques in the brains of people with Alzheimer's disease. I am not a participant in the pilot Seattle VA study..

Improving how the body uses insulin is a long term goal; maybe will help slow progress of memory loss.

May 2007 there was a New England Jounal of Medicine meta-analysis (this means an analysis of multiple scientific studies) that suggested a possible increased risk of cardiovascular death in patients on Avandia. It is important to remember that this was just one article, and furthermore it's an analysis of other studies, not a primary study (thus, is prone to some possible statistical problems and other problems inherent to such studies). The interesting thing about these finding, if true, is that by its mechanism of action many doctors had felt it might be useful to ward off diabetes in prediabetic patients, which should improve their life expectancy and risk of cardiovascular disease. There were also some who thought Avandia and/or other thiazolidinediones might be beneficial in those with early cardiovascular disease. I think the jury is still out on this issue of whether Avandia in fact increases risk of cardiovascular disease, but unfortunately it looks like this case might be tried in the press.

Diabetes drugs 'pose heart risk'[edit]

"Two drugs commonly prescribed to treat type 2 diabetes double the risk of heart failure, a study of data on more than 78,000 patients suggests."

"More than 1.5 million prescriptions for rosiglitazone and pioglitazone were issued in England alone last year.

"The researchers, led by the University of East Anglia, suggest fluid retention caused by the drugs may be to blame.

"Writing in the journal Diabetes Care, they call for a rethink on the drugs by the regulatory authorities."

drh 14:14, 27 July 2007 (UTC)

Fracture risk[edit]

Ouch. Fvasconcellos (t·c) 10:59, 11 January 2009 (UTC)

Tiazolidinediona - Covid19[edit]

Studies have found that taking Tiazolidinedione worsens COVID19 — Preceding unsigned comment added by (talk) 20:48, 14 March 2020 (UTC)